Search results for: Multi-Indication Medicines
Filter search results
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
…Intellectual Property. [online] Available at: https://www.efpia.eu/about-medicines/development-of-medicines/intellectual-property/ [Accessed 11 Apr. 2024]. European Medicines Agency and Sonia Ribeiro, 2018. Data exclusivity, market protection, orphan and paediatric rewards. [online] Available at: https://www.ema.europa.eu/en/documents/presentation/presentation-data-exclusivity-market-protection-orphan-and-paediatric-rewards-s-ribeiro_en.pdf [Accessed 5 Apr. 2024]. European…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
13 January 2020
…for medicines for more common conditions, may not be appropriate for medicines for ultra-rare conditions. Previous OHE research on availability and access to medicines for rare conditions (also known as…
What the first EU JCA reveals about assessing precision oncology
28 July 2026
…population, it also means that a single JCA may need to evaluate evidence generated across multiple tumour types, each with different comparators, treatment pathways, and standards of care, but often with a small or immature evidence base. Meeting the evidence requirements for multiple…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…A. & Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/indication-based-pricing-ibp-discussion-paper-should-drug-prices-differ-indication Lakdawalla, D., MacEwan, J.P., Dubois, R., Westrich, K., Berdud,…
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
23 September 2026
…across bevacizumab’s four already-recommended indications. The NMB achieved through BEAR for mCRC alone over three years is equal to 15% of the savings from the other four indications over six…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
…lead indications were consistent with previous findings; to our knowledge, this is the first analysis of discontinuations of follow-on indications. Companies also were asked their opinions on what factors may…
The value of cell and gene therapies to the UK economy
20 October 2025
…projected to create value between £20-40 billion across the four case study indications, depending on the category of value considered. AD dominates the aggregate because of its prevalence, but every indication is…
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…15 years to around 10. Companies may need to think more strategically about launch indications. Importantly, incentives for manufacturers to research and invest in new indication launches for existing therapies…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
…of existing drugs, which represents a critical source of treatment advances for patients, particularly in areas such as oncology and rare disease. Considering the dominance of multi-indication drugs in some…